Back to Newsroom

Symic​ ​Bio​ ​Enrolls​ ​First​ ​Patient​ ​in​ ​MODIFY2​ ​Phase​ ​2​ ​Trial​ ​of​ ​SB-061​ ​for​ ​the Treatment​ ​of​ ​Osteoarthritis

SAN​ ​FRANCISCO,​ ​Aug.​ ​23,​ ​2017​ – Symic Bio, a biopharmaceutical company developing novel matrix regulators, today announced the treatment of the first patient in the MODIFY2 Phase 2 clinical trial investigating SB-061 for pain management in mild-to-moderate osteoarthritis of the knee. The initiation of the 12-week, multicenter, double-blinded trial of approximately 60 patients follows previously announced Phase 1/2a clinical results supporting the safety, tolerability and intended mechanism of action of SB-061.